Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $22.00 by Analysts at HC Wainwright

Viridian Therapeutics (NASDAQ:VRDN) had its price objective trimmed by HC Wainwright from $34.00 to $22.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

VRDN has been the topic of several other reports. UBS Group initiated coverage on Viridian Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. Truist Financial lowered their price target on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Wall Street Zen downgraded shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, January 21st. Finally, Needham & Company LLC decreased their target price on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $39.21.

Viridian Therapeutics Stock Up 5.6%

VRDN stock opened at $19.56 on Tuesday. The stock has a market capitalization of $2.00 billion, a P/E ratio of -5.95 and a beta of 1.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65. Viridian Therapeutics has a one year low of $9.90 and a one year high of $34.29. The company has a 50 day moving average price of $29.16 and a two-hundred day moving average price of $27.89.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. As a group, sell-side analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.

Institutional Trading of Viridian Therapeutics

Institutional investors have recently modified their holdings of the company. Simplify Asset Management Inc. acquired a new position in Viridian Therapeutics during the third quarter valued at approximately $1,079,000. Hudson Bay Capital Management LP increased its position in shares of Viridian Therapeutics by 46.6% in the third quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company’s stock worth $3,782,000 after acquiring an additional 55,689 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Viridian Therapeutics by 135.6% in the 3rd quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock valued at $25,922,000 after acquiring an additional 691,267 shares during the period. Propel Bio Management LLC acquired a new position in shares of Viridian Therapeutics during the 3rd quarter valued at $1,942,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Viridian Therapeutics by 430.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company’s stock valued at $1,394,000 after acquiring an additional 52,414 shares in the last quarter.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short‑term selling pressure. Investing.com

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.